151 results about "ACUTE INFLAMMATIONS" patented technology

An inhibitor of a glutaminyl peptide cyclotransferase, and use thereof for the treatment and / or prevention of a disease or disorder selected from the group consisting of inflammatory diseases selected froma. neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis,b. chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis,c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis,d. cancer, e.g. cancer / hemangioendothelioma proliferation, gastric carcinomas,e. metabolic diseases, e.g. hypertension,f. and other inflammatory diseases, e.g. neuropathic pain, graft rejection / graft failure / graft vasculopathy, HIV infections / AIDS, gestosis, tuberous sclerosis.Additionally disclosed are a respective diagnostic method, assay and kit.

The invention discloses an application of anemoside B4 used as an immunomodulator to drugs for treating acute inflammations. The anti-inflammatory effect of the anemoside B4 is directly produced through inhibition of lymphocyte activation and inflammatory factor secretion. The application of the anemoside B4 used as the immunomodulator to the drugs for treating acute inflammations is disclosed for the first time, and the anemoside B4 belongs to a purely natural preparation, is safe, reliable and free of side effects and has potential development value for the drugs for treating acute inflammations.

The invention discloses a double detection line SAA (Serum amyloid A protein) immunofluorescence chromatography quantitative detection reagent and a preparation method thereof. The double detection line SAA immunofluorescence chromatography quantitative detection reagent can simultaneously promote sensitivity and detection scope and can be applied to clinical detection for SAA level in patients of acute inflammation and chronic inflammation. According to the technical key points, the reagent comprises a base plate, a combining cushion, a coating film and an absorbing cushion, wherein a sample cushion is connected with the base plate; anti-SAA monoclonal antibody 1 and chick IgY are sprayed on the combining cushion and are marked with a same fluorescent microsphere; a detection line T1, a detection line T2 and a quality control C line are arranged on the coating film; anti-SAA monoclonal antibody 2 is coated with the detection line T1; antigen SAA protein is coated with the detection line T2; goat-anti-chick IgY is coated with the quality control C line. The reagent belongs to the technical field of in-vitro diagnostic reagents.

An object of the present invention is to provide a compound having a novel structure for overcoming the defects of conventional steroid agents and NSAIDs. It is found that the particular dihydroxy bodies of eicosapentaenoic acid and docosahexaenoic acid, which have not conventionally been known (11,18-dihydroxy eicosapentaenoic acid (11,18-diHEPE), 17,18-dihydroxy eicosapentaenoic acid (17,18-diHEPE) etc.), have activity of inhibiting neutrophil, thereby solving the object. The present invention unexpectedly remarkably inhibits infiltration into a tissue of, and activation of neutrophil found out at acute inflammation. The compound of the present invention is a compound which has not conventionally been known. Therefore, utility as a new therapeutic is provided.

In the present invention, Applicants demonstrate the effect of a biomembrane sealing agent on the development of chronic pain following tissue injury as well as acute pain in a model of acute inflammation. Applicants demonstrate the ability of this class of agents referred to as “biomembrane sealing agents” to reduce the severity of hyperalgesia and allodynia following mechanical insult to the nervous system as well as their ability to reduce acute pain in a model of acute inflammation. Applicant describes the use of injectable or depot formulations of biomembrane sealing agent(s) for prophylactic treatment such as they could be administered after the insult (i.e. post-injury or post-surgery) but before the onset of acute or chronic pain. Alternatively, biomembrane sealing agents could be used to reduce the severity of acute or chronic pain after onset.

Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.

The invention discloses novel a chalcone compound extracted and purified from Oxytropis falcate, a preparation method and an application thereof. Identified through a spectral method, the novel chalcone compound has the structural formula C15H1203 and is named 2', 4'-dihydroxy chalcone, and the preparation method combines column chromatography and preparative liquid purification method. Result from experiments in vitro shows that the novel chalcone compound can remarkably restrain the growth and proliferation of tumor cells and has good efficacy of restraining acute inflammation of mice and chronic inflammation of rats. Therefore, the novel chalcone compound is expected to be developed to be a new generation of antitumor drugs or anti-inflammatory drugs.

Formulations and methods for preventing, inhibiting or controlling metabolic disorder, age-related disease and acute inflammations have been developed. The compositions comprise of bilirubins, bilirubin derivatives, their tetrapyrrolic analogues, tripyrroles, and dipyrroles. The compositions can be administered as a dosage form for oral ingestion, injection, suppository, or topical application. The effective amount of the compound is typically from 0.001-100 mg / kg body weight, preferably in the range from 0.01-50 mg / kg body weight, and most preferably from 0.05-10 mg / kg body weight. Examples demonstrate the efficacy of the compounds in both in vitro and in vivo tests.

The invention relates to a RANKL-TNF sample region mouse monoclonal antibody and its preparation method and use. The RANKL-TNF sample region mouse monoclonal antibody is extracted from a RANKL-TNF sample region mouse monoclonal antibody hybridoma cell strain and has the preservation number of CGMCC NO.6853. The RANKL-TNF sample region mouse monoclonal antibody and its related reagents can effectively neutralize TNF-alpha in vitro thereby inhibiting cell apoptosis caused by TNF-alpha, and neutralize RANKL in vitro thereby inhibiting osteoclast generation. The RANKL-TNF sample region mouse monoclonal antibody can effectively relieve an acute inflammation degree, improve bone mass of a mouse suffering from osteoporosis, improve a cancellous bone trabecula microstructure, and effectively improve osteoporosis symptoms.

Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.

The invention discloses a panda source lactobacillus plantarum and application. The strain was preserved in China Center for Type Culture Collection on May 4, 2016 and the preservation number is CCTCC NO: M2016245. The panda source lactobacillus plantarum provided by the invention can be used for improving antibody levels of IgA, IgM and IgG immune globulins of blood serum; a condition that the percent of lymphocytes is reduced and the percent of neutrophils is increased, caused by infection and induction of enterotoxigenic escherichia coli, is inhibited; expression levels of inflammation related factors IL-1beta, IL-8, IL-6, TLR4 and MyD88mRNA (messenger Ribonucleic Acid) are remarkably down-regulated, and intestinal acute inflammation response caused by the enterotoxigenic escherichia coli is alleviated.

The invention discloses a nutriment for improving the immunity of patients suffering from tumors after operation, radiotherapy and chemotherapy and a preparation method of the nutriment, and belongs to the technical field of medical foods. The nutriment comprises 45-98g / L of protein, 22-48g / L of fat, 98-245g / L of carbohydrate, 0-18g / L of dietary fibers, 0.35-0.75g / L of vitamins, 3.6-7.2g / L of trace elements, 1.0-2.2g / L of nucleotide, 0.2-20g / L of arginine, 0-0.2g / L of taurine, and an appropriate amount of water. The nutriment has various nutrient components, is rich in glutamine, arginine, nucleotide, omega-stability fatty acid and the like, is scientific in proportion, improves the nutritional status of patients, improves the resistance power of patients during operation, and after operation, radiotherapy and chemotherapy, improves the immunity of organisms of the patients, controls the acute inflammation, protects the function of intestinal mucosal barrier, reduces complication, shortens hospital days and reduces treatment price.

A compound for the manufacturing of a medicament for reducing or preventing mesothelial cell damage includes a mixture of a carrier gas and between 1 volume percent and 29 volume percent of nitrous oxide gas (N2O) and can be used for prevention of adhesion formation, pain reduction, reducing or preventing acute inflammation, reducing or preventing CO2 resorbtion or reducing tumor cell implantation upon surgery.

The invention belongs to the fields of natural medicines and cosmetics, and discloses applications of Chinese torreya essential oil in preparing medicines for treating inflammation-related diseases, and applications of Chinese torreya essential oil as the functional component in the cosmetics, so that the anaphylactic reaction of the cosmetics is reduced, and the anti-inflammatory repairing capacity of the skin is improved. The animal inflammation experiment proves that no matter after Chinese torreya essential oil is taken orally or externally applied, the mouse acute inflammation caused by egg white can be obviously inhibited, and in addition, the mouse acute inflammation caused by carrageenin also can be obviously inhibited. Chinese torreya essential oil is prepared from Chinese torreya aril through a distillation method, a cold pressing method, a solvent extraction method or a CO2 supercritical extraction method. The requirements for the quality of the Chinese torreya essential oil are as follows: the colourless or chartreuse liquid adopted has the characteristic aroma of Chinese torreya fruits, and has the relative density (at 20 DEG C / 20 DEG C) being 0.850-0.860, and the sum of the contents of the characteristic components alpha-pinene and limonene is greater than or equal to 30%. The invention discloses the novel applications of Chinese torreya essential oil in preparing the anti-inflammatory medicines or cosmetics. In addition, by comparing the advantages and disadvantages of different extraction methods of Chinese torreya essential oil, the invention provides a preferable preparation method of Chinese torreya essential oil.

The present invention provides methods for treating animals having acute inflammatory conditions, including mastitis, by administering at least one p38 MAP kinase inhibitor. The present invention also provides methods for enhancing milk production and reducing milk discard in animals afflicted with acute inflammatory conditions by administering at least one, p38 MAP kinase inhibitor.

The invention relates to a throat-clearing traditional Chinese medicine buccal tablet and a preparation method of the throat-clearing traditional Chinese medicine buccal tablet. The throat-clearing traditional Chinese medicine buccal tablet is constituted by the following elements in parts by weight: 10-80 parts of mixed extracts of Loniceramacranthoides Hand. flower bud and Chrysanthemum morifolium Ramat., 20-90 parts of a filler, 0.5-5 parts of an adhesive, 0.5-3 parts of a lubricant and 1-10 parts of a corrective; and the throat-clearing traditional Chinese medicine buccal tablet is obtained through steps of extracting the mixture, breaking, mixing uniformly, pelletizing, drying, granulating and pressing into tablets and the like. The buccal tablet provided by the invention has a function of resisting against acute inflammation and is safe and free from poison. The processing method is simple, and the cost is low.

The invention discloses the application of cyaniding 3-O-glucoside to the preparation of drugs or foods for preventing and controlling rheumatoild disease. The cyaniding 3-O-glucoside has better abirritation and acute inflammation resistance functions, and more importantly has the function of resisting the adjuvant-induced rheumatoild disease. A cytology experiment in vitro shows that the cyaniding 3-O-glucoside can inhibit the NO release of macrophage, thereby showing that the functions of anti-inflammation, analgesic effect and adjuvant-induced rheumatoild disease resistance are mainly derived from the strong inhibiting ability. The multiple effects of the cyaniding 3-O-glucoside lead the advantages on the aspect of controlling the rheumatoild disease to be more obvious. The cyaniding 3-O-glucoside is derived from wholefood, is efficient and innoxious, has extremely high safety, and thus has wide application prospect for controlling the rheumatoild disease in clinic.

The invention relates to a traditional Chinese medicine composition for treating local swelling and pain, belonging to the technical field of Chinese medicinal herbs. The composition is composed of the following active pharmaceutical ingredients: 10-100g of euphorbia perkinensis, 10-100g of euphorbia kansui, 10-100g of Brassica alba boiss, 4-6g of musk, 11-13g of ephedra, 29-31g of lumbricus, 17-19g of cassia twig, 8-10g of nux vomica and 29-31g of stalactite. By adopting the Chinese medicinal herb formula, the composition has the advantages of accessible materials, simple preparation method, favorable treatment effect and low price, has the effects of dispersing rheumatism, tonifying the liver and the kidney, dredging the channels and relieving numbness and pain, and is used for joint acute inflammation, morning stiffness, pain, swelling and dysfunction caused by rheumatic and rheumatoid arthritis and other rheumatic diseases.

The purpose is to provide a compound which can overcomes the disadvantages of conventional steroid drugs and NSAID. It is found that specific epoxy monohydroxy forms of eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid which are independently represented by formulae [chemical formula 1], [chemical formula 5] and the like have an inhibitory activity on neutrophils. This compound can inhibit the invasion of neutrophils into tissues and the activation of neutrophils which are observed in acute inflammations.

The present invention belongs to the field of medicine technology and discloses an effective dose containing acetylcysteine or pharmaceutically acceptable salts thereof, and at least one pharmaceutical composition of anti-infective drugs as well as usage and method for making same, wherein the antiinfective drugs are one or several compounds selected from new houttuynine sodium bisulfite or pharmaceutically acceptable salt thereof and / or 14-dehydroxyl-11, 12-dehydro andrographolide-3, 19-di-succinic acid half-ester salts and / or matrine. Said pharmaceutical composition can be made into pharmaceutically acceptable dosage forms and exhibits cooperative building action when being used for diseases such as pneumonia, bronchial asthma, haggis acute inflammation accompanying with chronic emphraxis haggis diseases caused by sensitive bacteria; in addition, possesses excellent stability, exhibits considerably improved effects relative to used individually medicament of the same dose, and results in effects beyond thoughts, possesses wide-ranging applications foreground.

The invention provides the application of carubinose in preparing medicine that can treat lung acute inflammation diseases. The molecular formula of carubinose is C6H12O6, the structure is D-carubinose. Said medicine comprises medicine acceptable shaping agent or carrying agent. The produced dosage form mainly comprises liquid dosage form, granule, tablet, gas spraying form, drop or pill. The invention can reduce the lung tissue TNF-alpha level of mice ALT model induced by LPS, release neutral granulocyte wettability in lung tissue, inhibit capillary blood permeability, decrease protein exudation and lung water content, reduce MPO level in BALF supernatant and improve pathologic change for lung tissue inflammation. The invention discloses the functions of anti-inflammation, anti-oxidation and pneumochysis reduction of carubinose.

The invention relates to an amlodipine besylate and atorvastatin calcium medicine compound liposome solid preparation which is prepared from amlodipine besylate and atorvastatin calcium medicine compound liposome and other solid preparation auxiliary materials; and the amlodipine besylate and atorvastatin calcium medicine compound liposome is prepared from benzene sulfonic acid amlodipine, atorvastatin calcium, soybean phosphatidyl glycerin, kennedy acute-inflammation sodium and cholesterol. Compared with traditional preparation, the preparation greatly improves the stability and the bioavailability, and has the advantages of stable medicine delivery, small side effect and more significant curative effect.

The invention belongs to the technical field of biomedicine and relates to an application of TFF2 protein in preparation of a medicine for treating and preventing lung / bronchial acute inflammation diseases. In the invention, the significantly different gene expression of the lung tissues of mice infected by severe flu and mild flu are analyzed and screened by a transcriptome chip, and the screened TFF2 is a protective factor; and according to in-vitro synthesis of TFF2 protein, the survival rate of the flu-infected mice can be remarkably increased by dropwise adding the TFF2 protein while the weight loss of mice is reduced. Further study shows that the TFF2 does not influence the flu virus replication but can reduce the secretion of inflammatory factors, promote the repair of the pulmonary mucosa and reduce the damage of lung tissues. Since the mechanism of other respiratory pathogens or physical and chemical factors causing respiratory tissue damage is similar to that of flu virus infection and the protection of TFF2 on flu virus infection is not specific protection but broad-spectrum protection, the TFF2 plays an important protection role in an acute inflammation damage model induced by respiratory pathogens or other factors.

A traditional Chinese medicine composition for fumigating to cure rheumatism, relates to traditional Chinese medicine formulas and is characterized by consisting of the following raw materials by weight: 30 parts of caulis piperis kadsurae, 30 parts of caulis sinomenii, 30 parts of erycibe obtusifolia, 50 parts of short-pedicel aconite roots, 30 parts of thunder god vines, 30 parts of caulis trachelospermi, 10 parts of erythrina indica lam, 9 parts of ningpo yam rhizome, 9 parts of pyrola, 9 parts of folium photiniae, 9 parts of cortex acanthopanacis, 15 parts of obscured homalomena rhizome, 12 parts of golden cypress, 9 parts ofrhizoma atractylodis, 9 parts of folium artemisiae argyi, 6 parts of snow lotus herbs, 3 parts of processed radix aconiti, 3 parts of processed radix aconiti kusnezoffii, 15 parts of of garden balsam stems and 9 parts of radix clematidis. The traditional Chinese medicine formula for curing the rheumatism is easy in obtaining materials, simple in preparation method, good in curative effects, low in price and capable of achieving the functions of removing the rheumatism, nourishing liver and kidney, clearing the meridians and stopping pain and numbness, and is used for joint acute inflammation, morning stiffness, pain, swelling and functional disorder caused by rheumatism arthralgia syndrome of rheumatic arthritis, rheumatoid arthritis and the like.

The invention relates to an anti-inflammatory effective part of a leaf of Santalum album L.. The anti-inflammatory effective part comprises vitexin, isovitexin and orientin, and the content of the vitexin, the isovitexin and the orientin in the effective part is not less than 80%. The invention further provides a preparation method and application of the anti-inflammatory effective part of the leaf of Santalum album L.. The anti-inflammatory effective part of the leaf of Santalum album L. is clear in chemical components and the content of the known components exceeds 80%; systematic anti-inflammatory experiments show that the effective part is effective in treatment of acute inflammation.

The invention discloses a lactobacillus plantarum Lp2. The preservation number of the lactobacillus plantarum Lp2 is CCTCC NO: M 2019935. A probiotic solid beverage comprises the following componentsin parts by weight: 10 parts of lactobacillus plantarum freeze-dried powder, 5-10 parts of isomaltooligosacharide, 5-10 parts of soybean oligosaccharide and 5-15 parts of fruity powder. The preservation number of the lactobacillus plantarum is CCTCC NO: M 2019935. The invention also discloses application of the lactobacillus plantarum Lp2 in preparation of anti-enteritis drugs. Results show that the lactobacillus plantarum Lp2 has good acid stress tolerance, cholate stress tolerance, pathogenic bacteria infection resistance and high intestinal tract colonization capacity, and has a protectiveeffect on LPS-induced acute inflammation; the lactobacillus plantarum Lp2 strain is superior to other strains in in-vitro probiotic function evaluation and in-vivo indexes of mice, and it is shown that lactobacillus plantarum Lp2 shows obvious strain specificity in the aspect of anti-inflammation.

The invention relates to application of sugar, in particular to the application of algin oligosaccharide. The invention is characterized in that the algin oligosaccharide is used as a bacteriostat of germs or epiphyte. The invention proves that the bacteriostat can effectively inhibit the growing of Gram-negative bacteria or positive bacteria by bacteriostatic experiments, and shows broad spectrum antibiotic activity; the algin oligosaccharide is proved to have an antiinflammatory action and certain abirritation by acute inflammation experiments on animals.

The invention relates to a preparation method of traditional Chinese medicine for treatment of yang deficiency, qi stagnation and blood stasis type chronic pelvic inflammatory disease, belonging to the technical field of a preparation method of traditional Chinese medicine. At present, the chronic pelvic inflammatory disease only includes tuberculous pelvic inflammatory disease and pelvic actinomycosis, and the pelvic inflammatory disease caused by other pathogens do not exist actually and are sequelaes of acute inflammation with no pathogen infection in tissues, which cannot be treated generally by western antibiotic treatment in the clinical practice. In the technical scheme, 12g of antler, 5g of baked ginger, 3g of fennel, 10g of cassia twigs, 10g of eucommia ulmoides, 10g of radix rehmanniae, 10g of codonopsis pilosula, 9g of angelica sinensis, 5g of pollen typhae, 9g of trogopterus dung, 9g of corydalis tuber, 9g of rhizoma sparganii, 9g of curcuma zedoary, 9g of radix linderae, 10g of radix astragali preparata, 6g of licorice are added into 1000ml of water, soaked for 30 minutes and then decocted by mild fire, the decocted medical solution is filtered by gauze, bottled and then sealed, and thus the traditional Chinese medicine for treatment of the yang deficiency, qi stagnation and blood stasis type chronic pelvic inflammatory disease is prepared. The invention has the advantages that the traditional Chinese medicine has smaller toxic and side effects, and the efficacy is long-lasting, stable and satisfactory after the medicine is taken.

The invention discloses an aspirin-based carbon quantum dot and application thereof in aspects of cell imaging and anti-inflammatory treatment, belonging to the technical field of nano-drugs. The invention in particular relates to a carbon quantum dot with strong fluorescent properties prepared from a hydrazine hydrate solution by utilizing a microwave heating method under the condition that aspirin dissolution is promoted. The carbon quantum dot prepared by the method is very stable under hyper-salt concentration and physiological pH conditions, blue-fluorescence is maintained, the carbon quantum dot can enter the cell nucleus, and the cells are effectively traced; and meanwhile, the original anti-inflammatory effect of aspirin is remained, and inflammatory cells can be effectively inhibited in an acute inflammation model constructed by utilizing carrageenin. In addition, the prepared aspirin carbon quantum dot is low in toxicity and does not influence liver and kidney functions and organs such as the heart, liver, spleen and kidney in in-vivo application, and the aim that the nanometer material has dual effects of diagnosis and treatment can be achieved.